A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
ClinicalTrials.gov ID
NCT01970137
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Apr 18, 2016Estimated
Primary Completion Date
Oct 2014Actual
Brief Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)
Spinocerebellar Degeneration
KPS-0373, High dose
KPS-0373, Low dose
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Japanese SCD patients with ataxia (Experience of clinical trials of KPS-0373)
Exclusion Criteria:
Patients with secondary ataxia
Patients with clinically significant hepatic, renal, or cardiovascular dysfunction
Discontinuations in another clinical trials caused by side effects